Fenoglio D, Puppo F, Cirillo I, Vizzaccaro A, Ferrera A, Tosca M A, Marseglia G, Ciprandi G
DIMI-CEBR, Università di Genova, Genoa, Italy.
Eur Ann Allergy Clin Immunol. 2005 Apr;37(4):147-51.
Subcutaneous specific immunotherapy has been demonstrated capable of inducing T regulatory response. There is few evidence concerning immunological changes induced by sublingual immunotherapy.
The aim of this study was to evaluate T cell proliferation in subjects successfully treated with SLIT for HDM.
PBMCs were isolated from patients after at least 3 years of successful HDM SLIT and from matched untreated allergic and healthy control subjects. After 3 and 6 days of in vitro stimulation with PHA, Candida albicans, Dermatophagoides farinae, grasses, Parietaria judaica, and cat, proliferation.
Subjects treated with SLIT showed significant reduction of proliferation induced by Candida albicans, Parietaria, and grasses in comparison with untreated atopics (p=0.0002, 0.0033, and 0.009 respectively).
This pilot study confirms reduced T cell proliferation in allergic subjects treated with SLIT.
皮下特异性免疫疗法已被证明能够诱导调节性T细胞反应。关于舌下免疫疗法引起的免疫变化的证据很少。
本研究的目的是评估成功接受舌下免疫疗法治疗屋尘螨的受试者的T细胞增殖情况。
从成功接受屋尘螨舌下免疫疗法至少3年的患者以及匹配的未治疗过敏对照受试者和健康对照受试者中分离外周血单核细胞。在体外用植物血凝素、白色念珠菌、粉尘螨、草、墙草和猫刺激3天和6天后，检测增殖情况。
与未治疗的特应性受试者相比，接受舌下免疫疗法治疗的受试者由白色念珠菌、墙草和草诱导的增殖显著降低（分别为p=0.0002、0.0033和0.009）。
这项初步研究证实接受舌下免疫疗法治疗的过敏受试者的T细胞增殖减少。
